Resiniferatoxin - Grunenthal
Alternative Names: Lopain; MTX-071; RTX - Grunenthal; RTX-GRT7039Latest Information Update: 01 Jan 2025
At a glance
- Originator Mestex AG
- Developer Grunenthal
- Class Acetates; Analgesics; Anti-inflammatories; Azulenes; Non-opioid analgesics; Phenols; Phenyl ethers; Small molecules
- Mechanism of Action TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Musculoskeletal pain
Most Recent Events
- 18 Nov 2024 Grünenthal completes a phase III trials in Musculoskeletal pain in Canada, Czechia, France, Germany, Italy, Japan, Mexico, Netherlands, Poland (Intra-articular, Injection) (EudraCT2021-005029-26) (NCT05248386)
- 14 Nov 2024 Pharmacokinetics and adverse events data in Musculoskeletal pain presented at the ACR Convergence 2024 (ACR-2024) .
- 12 Jun 2024 Adverse events and efficacy data from a phase II trial in Musculoskeletal pain presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)